Section Arrow
ARGX.NASDAQ
- argenx SE
Quotes are at least 15-min delayed:2025/03/28 00:16 EDT
Last
 593.47
+9.81 (+1.68%)
Day High 
596.905 
Prev. Close
583.66 
1-M High
650.79 
Volume 
362.59K 
Bid
440
Ask
892.26
Day Low
582.105 
Open
583.66 
1-M Low
562.96 
Market Cap 
35.60B 
Currency USD 
P/E 45.67 
%Yield -- 
10-SMA 605.67 
20-SMA 606.83 
50-SMA 631.63 
52-W High 678.21 
52-W Low 352.77 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
12.78/13.51
Enterprise Value
35.63B
Balance Sheet
Book Value Per Share
90.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.19B
Operating Revenue Per Share
16.29
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.